Skip to main content

CAMBRIDGE, Massachusetts (


) --



is exploring a new deal structure that could break an acquisition deadlock with



, the

Wall Street Journal


Genzyme is considering a structure known as a contingent value right, which gives shareholders an added benefit once an acquired company hits a future benchmark, the


Scroll to Continue

TheStreet Recommends


The CVR would be largely tied to the performance of Campath, a Genzyme drug used to treat leukemia but that is being tested for use on multiple sclerosis, people familiar with the matter told the newspaper.

Genzyme has been holding internal discussions about how to structure such a deal with Sanofi, the



Sanofi has said Genzyme is too optimistic in its projection for Campath's use on multiple sclerosis.

Genzyme has been trying to fend off an $18.5 billion hostile bid from France's Sanofi.

-- Written by Joseph Woelfel

>To contact the writer of this article, click here:

Joseph Woelfel

>To submit a news tip, send an email to: